

Effects of Citrulline Combined with Tadalafil on Monocrotaline-Induced Pulmonary Hypertension in Rats Compared with Arginine

Fuminobu Ishikura^{1*}, Mai Egawa², Yuri Takano², Kota Kumagai³, Takashi Suzuki³ and Masahiko Morita³

All rats '* ere induced pulmonar, h pertension b 5 time's subcutaneous injection of MCT (10 mg/kg/da))'* ithin 2'* eeks. Ne $t_{\rm g}$ '* e orall, administrated tadalå 1 (0.4 mg/kg/da) or saline (vehicle group) for 6 times ever other da. Citrulline and arginine (KYOWA HAKKO BIO CO., LTD., Tok, o, Japan)'* ere administered from '* ater suppl. (10 g/L) (Figure 1).

T^A is stud '* as approved by the Osaka Universit, Medical School Animal Care and Use Committee and '* as in compliance '* ith the Osaka Universit, Medical School Guidelines for the Care and Use of Laborator, Animals. All institutional and national guidelines for the care and use of laborator, animals'* ere follo* ed.

Estimation of cardiac function by echocardiography

Echocardiograph '* as performed at 6-* eeks and 8-* eeks. Rats * ere anesthetized '* th sodium pentobarbital (40 mg/kg, ip). Right and le ventricular end-diastolic area '* ere measured at the papillar muscle level using SONOS5500 (Philips Medical S stems, USA) * ith a9154710(94)(1fraton)0.068-d0.00847cStatus 0.048118740(US2) (frigure.833 99 At the aortic valve level in the short a is view, Pulmonar, arter (PA) o*

using log-rank anal ses of Kaplan-Meier curves. Statistical anal sis *as performed *ith Statcel so *are for Windors (Version 2, OMS Publishing, Inc., Saitama, Japan) and the stat 2000 Statistical Program File (Igaku Tosho Shuppan, Tok, o, Japan).

Results

Survival rate

 T^{A} e survival rate of a tadala 1 and citrulline group is much higher than other 4 groups (Figure 4). Hore ever T^{A} e survival rate of a tadala 1 and arginine group is almost same as that of a tadala 1 group.

Two-dimensional echocardiographic parameters

At 6'reeks, the ratio of right to le ventricular end-diastolic area in all groups ras almost same. At 8'reeks, the ratio of right to le ventricular end-diastolic area in 4 groups (tadala 1, citrulline, tadala 1 and citrulline, tadala 1 and arginine) ras lor er than that in a vehicle group (Figure 5).

Pulmonary artery ow

Ma imum of velocit of the pulmonar arter at 8 reeks in 4 groups e cept for a tadala l+arginine group is lower than that at 6

Citation:



E pression of PDE5 as found to be greater in lung tissues from patients with PH compared with controls [22]. Highle e pression of PDE5 in lung tissues causes e cess contraction of the pulmonar arter and leads to PH. Now PDE5 inhibitors are the rst line to treat patients with PH. PDE5 is the major negative regulator of cGMP. Its e pression has been observed in corpus cavernosum, vascular smooth muscle cells, and platelets. cGMP is one of the secondar messengers involved in the regulation of vascular homeostasis. Up-regulation of cGMP is a well-established strateg for vasodilatation and increased blood ow.

It is known that NO is e ective to improve PH [23]. NO increased the intercellular cGMP level b activating soluble guan late c clase (sGC), but cGMP is quickly broken down b $PDE5_{T}$, us, it is possible that combination of the PDE5 inhibitor and NO donor is very e ective to treat PH.

Horever, a direct NO donor, such as nitrogl_cerin is contraindication of concomitant use'rith PDE5 inhibitors. Arginine is amino acid and ph_siological substrate for NOS, so arginine could be concomitant use'r ith PDE5 inhibitors. Citrulline, one of the amino acid which is used as a safe food ingredient, [15,24] is not a direct NO donor, but citrulline is converted to arginine b, argininosuccinate s, nthetase. $_{T^{\Lambda}}$ e survival rate of a tadala 1 and arginine group is almost same as that of a tadala 1 group r_{r} e survival rate of a tadala 1 and citrulline group is much higher than other 4 groups involving in tadala l and arginine group. T^{Λ} is is because citrulline is a more e ective e tracellular supplement to enhance NO production. Diminished global arginine bioavailabilit_ratio is associated'# ith higher s_stolic pulmonar_arter pressure and higher central venous pressure [25]. In a stud, of orally ingested arginine, arginine is e tensivel metabolized by arginase in the intestine and liver $[26,27]_{T}$ is may limit its bioavailabilit as a substrate for NOS and subsequent e ects on vascular function. In contrast, citrulline is not metabolized in the gut rall or liver, and is more e ective in maintaining plasma arginine concentrations than arginine itself [11]. So, oral intake of citrulline increased plasma arginine and produced NO b_ NOS. NO up-regulated cGMP b_ sGC, and tadala 1 inhibited the PDE5 that breaks down the cGMP $_{T}$ defore combination of citrulline and tadala l increased cGMP e cientl Activation of NO-cGMP pathra, reads to vasodilatation and increased blood of $\uparrow \uparrow \uparrow$ at is $\uparrow \uparrow \uparrow$ the survival rate of a citrulline and tadala 1 group is much higher than arginine group. To our knothedge, this is the rst stud, to demonstrate the therapeutic e ect of the combination of tadala 1 and citrulline on PH.

Pulmonar_h_pertension is a disorder characterized b_ an increase in mean pulmonar, arterial pressure, which is responsible for the transport of blood from the heart to the lungs. Increased pulmonar vascular tone causes stricture of pulmonar, arter, and then leads to right ventriçular failure [28]. RV to LV veight in a tadala l group and a tadala 1+citrulline group rere lorer than other 3 groups. In addition, estimated pulmonar, arter, pressure in a citrulline and tadala 1+citrulline group seem to be lover than those in other groups. T^{Λ} is is because citrulline reduced right ventricular failure b, inducing vasodilation. Lor RV to LV'reight and estimated pulmonar arter pressure might result in improving survival rate in tadala 1+citrulline group T^{Λ} e survival rate in 4 groups e cept for a tadala 1+citrulline group is lor. So, re could not perform echocardiograph, for all rats, as rell as Vma of PA or and RVEDA/LVEDA ratio. Pulmonar h_pertension in survival rats might not be severe, so echocardiographic parameters rere almost same in 4groups r e survival rate and the ratio of RV to LV reight could be the most reliable data. In this stud, re didn't have blood pressure and histopathological data. It has been reported that oral administration of citrulline suppressed the increase of blood pressure and lung histopathological changes in pulmonar h pertensive rats $[8,10]_{T}$, erefore, the e cac of tadala 1 + citrulline in preventing deterioration of pulmonar, h pertension is likel, to be partiall mediated b these e ects.

We tried to establish a rat model of pulmonar h pertension' ith su cient tricuspid regurgitation b 15 times injections of 5 mg/kg/da of MCT. In this model, we obtained su cient tricuspid regurgitation in 78% of rats. Other parameters, such as right ventricle area and right ventricle or lung' eight, in the PH group were greater than those in the control group, and AT/ET and VTI in the PH group were smaller than those in the control group $\frac{1}{2}$ of ndings were ver almost similar to those in other reports [6,7,21].

It is more e ective to administrate tadala l ever da , but to be performed forced oral dosage is ver stressful for rats and a ects survival rate T^{A} erefore e orall administrated tadala l for 6 times ever other da in this stud. In this condition, the combination of tadala l and citrulline demonstrated survival bene t. It is possible that administrating tadala l e ith citrulline ever da is more e cient therapeutic e ect on PH.

Conclusion

Combination therap, of tadala l and citrulline might be useful to prevent deterioration of pulmonar, h pertension and improve survival rate compared with concomitant use of arginine.

Con ict of interest

Fuminobu Ishikura, Mai Egara, Yuri Takano, Kota Kumagai, Takashi Suzuki and Masahiko Morita declare that have no con ict of interest.

References

Citation: